Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

121. Strontium ranelate (Protelos) - Treatment of osteoporosis in men at increased risk of fracture

Strontium ranelate (Protelos) - Treatment of osteoporosis in men at increased risk of fracture Published 08 October 2012 Statement of Advice strontium ranelate (Protelos®) 2g granules for oral suspension (No: 816/12) Servier Laboratories Limited 7 September 2012 ADVICE: in the absence of a submission from the holder of the marketing authorisation strontium ranelate (Protelos ®) is not recommended for use within NHS Scotland. Indication under review: Treatment of osteoporosis in men at increased

Scottish Medicines Consortium2012

122. Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms

Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms Gauthier K, Bai A, Perras C, Cunningham J, Ahuja T, Richter T, Kovacs C Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Gauthier K, Bai A, Perras C, Cunningham J, Ahuja T, Richter T, Kovacs C. Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions Evidence from six placebo-controlled randomized

Health Technology Assessment (HTA) Database.2012

123. Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report

Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report Crandall CJ, Newberry SJ, Gellad WG, Diamant A, Lim YW, Suttorp M, Motala A, Ewing B, Roth B, Timmer M, Shanman R, Shekelle PG Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Crandall CJ, Newberry SJ, Gellad WG, Diamant A, Lim YW, Suttorp M, Motala A, Ewing B, Roth B, Timmer M, Shanman R, Shekelle PG. Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review

Health Technology Assessment (HTA) Database.2012

124. Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines

Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines CADTH Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions Denosumab and zoledronic acid were shown to be safe

Health Technology Assessment (HTA) Database.2012

125. Review: Teriparatide reduces fractures in postmenopausal women with osteoporosis.

Review: Teriparatide reduces fractures in postmenopausal women with osteoporosis. ACP Journal Club. Review: teriparatide reduces fractures in postmenopausal women with osteoporosis. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create (...) File 1 selected item: 22986396 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Sep 18;157(6):JC3-4. doi: 10.7326/0003-4819-157-6-201209180-02004. ACP Journal Club. Review: teriparatide reduces fractures in postmenopausal women with osteoporosis. . Comment on [Int J Clin Pract. 2012] PMID: 22986396 DOI: Publication type Full

Annals of Internal Medicine2012

126. Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis

Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis Kingkaew P, Maleewong U, Ngarmukos C, Teerawattananon Y (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study assessed the cost-effectiveness of strategies of systematic screening for osteoporosis among postmenopausal women and medical treatments for those diagnosed positive. The authors

NHS Economic Evaluation Database.2012

129. Bisphosphonates for Osteoporosis - Where Do We Go from Here?

Bisphosphonates for Osteoporosis - Where Do We Go from Here? Bisphosphonates for osteoporosis--where do we go from here? - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 22571168 Format MeSH and Other Data E (...) -mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 May 31;366(22):2048-51. doi: 10.1056/NEJMp1202619. Epub 2012 May 9. Bisphosphonates for osteoporosis--where do we go from here? 1 , , , . 1 Division of Reproductive and Urologic Products, Office of New Drugs, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, USA. PMID: 22571168 DOI: [Indexed

NEJM2012

130. Continuing Bisphosphonate Treatment for Osteoporosis - For Whom and for How Long?

Continuing Bisphosphonate Treatment for Osteoporosis - For Whom and for How Long? Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item (...) : 22571169 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 May 31;366(22):2051-3. doi: 10.1056/NEJMp1202623. Epub 2012 May 9. Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? 1 , , , , . 1 Department of Epidemiology and Biostatistics, University of California, San Francisco, USA. PMID: 22571169 PMCID

NEJM2012 Full Text: Link to full Text with Trip Pro

131. Taking Bisphosphonates For Osteoporosis Increases The Risk Of Osteonecrosis Of The Jaw Only Slightly

Taking Bisphosphonates For Osteoporosis Increases The Risk Of Osteonecrosis Of The Jaw Only Slightly UTCAT2269, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Taking Bisphosphonates For Osteoporosis Increases The Risk Of Osteonecrosis Of The Jaw Only Slightly Clinical Question In a patient currently taking oral bisphosphonates, what is the likelihood of bisphosphonates induced osteonecrosis after dental extractions (...) ? Clinical Bottom Line In patients taking oral bisphosphonates, the risk of bisphosphonate induced osteonecrosis after dental extraction is slightly increased. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Pazianas/2007 11 publications reporting 26 cases of ONJ in patients receiving bisphosphonates for the treatment of osteoporosis Systematic Review of: case reports, case series and observational studies

UTHSCSA Dental School CAT Library2012

132. Relationship Between Osteoporosis and Periodontal Disease Has Not Been Established

Relationship Between Osteoporosis and Periodontal Disease Has Not Been Established UTCAT2217, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Relationship Between Osteoporosis and Periodontal Disease Has Not Been Established Clinical Question Do patients with osteoporosis have a higher incidence of periodontal disease than the general population? Clinical Bottom Line The relationship between osteoporosis (...) and periodontal disease cannot be established based on available data. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Martinez-Maestre/2010 35 selected trials Systematic review of clinical trials Key results Few studies have been performed to demonstrate an association between systemic osteoporosis and fractures to dental loss. Most, from the few done, have found a positive correlation (five out of seven

UTHSCSA Dental School CAT Library2012

134. The economics of improving medication adherence in osteoporosis: validation and application of a simulation model

The economics of improving medication adherence in osteoporosis: validation and application of a simulation model The economics of improving medication adherence in osteoporosis: validation and application of a simulation model The economics of improving medication adherence in osteoporosis: validation and application of a simulation model Patrick AR, Schousboe JT, Losina E, Solomon DH Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of a hypothetical behavioural intervention to improve adherence to osteoporosis medication in women starting bisphosphonate therapy. The authors concluded that behavioural interventions were likely to be cost-effective in most scenarios, especially

NHS Economic Evaluation Database.2012

136. Bone-density testing interval and transition to osteoporosis in older women.

Bone-density testing interval and transition to osteoporosis in older women. BACKGROUND: Although bone mineral density (BMD) testing to screen for osteoporosis (BMD T score, -2.50 or lower) is recommended for women 65 years of age or older, there are few data to guide decisions about the interval between BMD tests. METHODS: We studied 4957 women, 67 years of age or older, with normal BMD (T score at the femoral neck and total hip, -1.00 or higher) or osteopenia (T score, -1.01 to -2.49 (...) ) and with no history of hip or clinical vertebral fracture or of treatment for osteoporosis, followed prospectively for up to 15 years. The BMD testing interval was defined as the estimated time for 10% of women to make the transition to osteoporosis before having a hip or clinical vertebral fracture, with adjustment for estrogen use and clinical risk factors. Transitions from normal BMD and from three subgroups of osteopenia (mild, moderate, and advanced) were analyzed with the use of parametric cumulative

NEJM2012 Full Text: Link to full Text with Trip Pro

137. Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis

Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis Mueller D, Gandjour A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness and budget impact of secondary plus tertiary prevention of osteoporosis by identifying post-menopausal women who were at increased risk of fractures, compared with tertiary prevention alone. The authors concluded that both prevention strategies were cost-effective compared with no prevention. Secondary plus tertiary prevention was more effective and more

NHS Economic Evaluation Database.2012

138. Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age

Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age Article Text Economic analysis Screening for postmenopausal osteoporosis with any modality is cost-effective including

Evidence-Based Medicine (Requires free registration)2012